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Abstract 
 
 
 
In diabetes, pharmacogenetics can be used both to identify patient subgroups who will have 
most benefit and/or least harm from a particularly treatment, and to gain insights into the 
molecular mechanisms of drug action and disease aetiology.  There is increasing evidence 
that genetic variation alters response to diabetes treatments – both in terms of glycaemic 
response and side effects.  This can be seen with dramatic impact on clinical care, in 
patients with genetic forms of diabetes such as Maturity Onset Diabetes of the Young 
caused by HNF1A mutations, and Neonatal diabetes due to activating mutations in ABCC8 or 
KCNJ11.   Beyond monogenic diabetes, pharmacogenetic variants have yet to impact on 
clinical practice, yet the effect sizes (e.g. for metformin intolerance and OCT1 variants; or for 
metformin action and SLC2A2 variants) are potentially of clinical utility, especially if the 
genotype is already known at the point of prescribing.   Over the next few years, increasing 
cohort sizes and linkage at scale to electronic medical records will provide considerable 
potential for stratification and novel target identification in diabetes.    
Introduction 
 
Pharmacogenetics is the study of how genetic variation modifies drug action.  Drug action 
here is a broad term that, when considering treatment of patients with diabetes, can 
include glycaemic response, adverse drug reactions including drug side effects, 
cardiovascular risk reduction, and reduction in microvascular disease progression.  As will be 
discussed later, it is important to consider these potential drug effects as we aim to better 
target treatment based upon genetic and non-genetic characteristics of patients, but the 
focus of this review will be on glycaemic benefit and drug side effects as these have been 
studied more extensively than longer term outcomes.   
 
Traditionally pharmacogenetics has focused on the goal of identifying patients or patient 
subgroups who should be targeted with one drug in preference to another, based on a 
predicted differential response to the two drugs, or predicted likelihood of side effect or 
harm.  However, with increasingly deep phenotyping of patients, including molecular 
phenotyping, the application of pharmacogenomics can be used as a complementary tool to 
traditional disease genetics to identify aetiological signatures of disease, as well as 
molecular signatures of drug action.  Both latter approaches can help unravel the biology of 
disease and disease specific mechanisms of a drug, resulting in the potential for the 
identification of novel drug targets. 
 
As highlighted in the figure, there are two parallel approaches to pharmacogenetics.  One 
approach focuses initially on disease aetiology, the other on initially on a drug intervention.   
The aetiological approach uses increasingly large case control studies to investigate the 
genetic basis of type 2 diabetes.  Combined with careful clinical, physiological and molecular 
phenotyping, this may be used to identify patients who are pathophysiologically distinct 
from other patients who, therefore, are more likely to respond to a drug that targets that 
pathophysiology.  The alternative approach is to consider how genetic variation is 
associated with variation in glycaemic response to drugs.  In this way groups of patients may 
be identified who are predicted to respond well or poorly to a drug.  These patients may 
differ by pathophysiology and as such may overlap with patients identified via the disease 
aetiology route, or they may reflect other differences in drug pharmacodynamics or 
pharmacokinetics. 
 
 
Disease aetiology and drug response 
 
The monogenic diabetes paradigm. 
Patients with diabetes caused by heterozygous mutations in HNF1A, causing a type of 
Maturity Onset Diabetes of the Young (MODY), are often diagnosed incorrectly as type 1 or 
type 2 diabetes and treated with insulin or other type 2 diabetes treatments.  HNF1A 
mutations result in a defect in glycolysis and mitochondrial metabolism resulting in impaired 
glucose stimulated insulin secretion, yet the KATP channel which sulphonylureas act to close, 
and the downstream signalling mechanisms, remain intact. Thus, these patients are 
exquisitely sensitive to sulphonylurea treatment when compared to age and BMI matched 
patients with type 2 diabetes { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}, and this sensitivity 
to sulphonylureas is so marked that patients who have been diagnosed with type 1 diabetes 
and insulin treated for up to 35 years could transition off insulin onto oral sulphonylurea 
treatment { ADDIN EN.CITE 
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urls></urls></record></Cite></EndNote>}.  An even more striking example of disease 
aetiology altering diabetes treatment can be seen in neonatal diabetes caused by KATP 
channel gene mutations.  Neonatal diabetes presents within the first 6 months of life, with 
marked hyperglycaemia and often ketoacidosis, requiring insulin treatment.  Within the last 
10 years, activating mutations in the KATP channel genes (ABCC8 and KCNJ11) have been 
identified that account for approximately half of all cases of neonatal diabetes { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}.  Once the genetic aetiology was determined, it was 
hypothesised that sulphonylureas might close the KATP channel and trigger insulin secretion. 
This was established, albeit with high dose sulphonylureas required to overcome the KATP 
channel defect, and patients with lifelong diabetes have been able to successfully transition 
off insulin on to oral sulphonylurea therapy with improved glycaemic control { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}. 
 
 
From monogenic diabetes to polygenic disease. 
There is some evidence that the monogenic diabetes paradigm does translate to type 2 
diabetes but, as could have been anticipated because the effect sizes of the diabetes 
associated variants are far smaller than seen with mendelian disease, the pharmacogenetic 
effect size is much smaller and has not yet translated to clinical care.  Currently the only 
reported diabetes risk gene – drug interactions are in relation to variants in TCF7L2, 
KCNJ11/ABCC8 and PPARG.   
 
The first type 2 diabetes variant established to alter glycaemic response to treatment was at 
the TCF7L2 locus, where participants in the GoDARTS study, with type 2 diabetes carrying 
two risk variants at rs12255372 were more likely not to achieve a treatment HbA1c <7% 
(53mmol/mmol) (OR 2.16 (1.21- 3.86), p=0.009) than patients with no risk variants at this 
SNP, in response to sulphonylurea treatment { ADDIN EN.CITE 
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been subsequently replicated { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  Srinivasan et al. 
analysed the effect of the TCF7L2 diabetes risk variant rs7903146 on the acute response to 
glipizide and to metformin in the SUGAR-MGH cohort { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}.  This cohort is undertaken in people not known have diabetes, who are 
given a single dose of glipizide, and on separate occasion a 75g OGTT following 2 days of 
metformin given 500mg twice daily.   In this study, in contrast to the studies reporting 
reduced efficacy of sulphonylureas in patients with diabetes, the diabetes risk variant is not 
associated with the glucose lowering achieved by a single dose of glipizide, although the risk 
variant was associated with lower glucagon prior to and following glipizide dosing.  
Interestingly the diabetes risk variant was associated with a greater response to metformin, 
an effect that was not observed in the GoDARTS study in participants with type 2 diabetes { 
ADDIN EN.CITE 
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between these results may reflect that the physiological studies are an acute dosing in 
people not known to have diabetes compared to chronic dosing in patients with established 
diabetes.  More work is clearly required to establish if and how TCF7L2 variants alter 
response to sulphonylureas and metformin in patients with type 2 diabetes. 
 
Secondly, the E23K/S1369A variant at the KCNJ11/ABCC8 gene was also reported to alter 
sulphonylurea response.  Here in contrast to TCF7L2, the diabetes risk variant is associated 
with greater response to sulphonylureas { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}; this 
contrast highlights how all beta-cell variants cannot be considered equal and that the site of 
the defect within the beta-cell determines whether the response to sulphonylureas is 
increased or reduced.  Another replicated finding is the association between the PPARG 
Pro12Ala diabetes risk variant and response to thiazolidinediones. A few studies, albeit each 
with fewer than 200 participants, have consistently reported that the T2DM risk Pro allele is 
associated with poor glycaemic response { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
 
Beyond these reported drug-gene interactions, there have been no other reported associations 
of genetic variants that alter diabetes risk with glycaemic response to any of the diabetes 
treatments, even though there are now over 400 robustly replicated type 2 diabetes risk 
variants { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  This probably reflects that the 
pharmacogenetic community lag the disease genetics community with regards to sample size 
and available genetic data – most of the risk variants have very small effects and these are 
unlikely to have a measurable impact on diabetes drug response in the few thousand patients 
that represent the largest pharmacogenetics cohorts to date. However, it should be noted that 
in this GWAS of ~900k individuals, the top 2.5% of the genetic risk distribution have a 9-
fold increase in risk for diabetes; thus even though individual variants are small, the 
combined effect can be large. If these genetic variants can be grouped into 
pathophysiologically similar subgroups, it may be that a genetic risk score of these subgroup 
variants will impact on glycaemic response to a drug that targets that pathophysiological 
defect.  Furthermore, 14 low frequency and rare variants are identified that have a large effect 
size (OR for diabetes risk >2).  In some populations, large effect variants can be found at 
relatively high frequency. One potential example that may rapidly translate into a stratified 
therapeutic approach is the finding that a rare missense variant in HNF1A is associated with 
type 2 diabetes risk in a Latino population { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
The risk variant is present in 2.1% of the population with type 2 diabetes.  Given the 
previously described extreme sensitivity to sulphonylureas in patients with mendelian 
mutations in HNF1A, it seems likely that this subgroup of Latinos will respond well to 
sulphonylurea therapy although this remains to be established.   
Expanding the aetiological subtypes of diabetes 
Even though we have long acknowledged that type 2 diabetes is a pathophysiologically 
heterogeneous disease, there has been little attempt to tease this group apart into 
pathophysiologically similar groupings.  A recent elegant recent study has done just this, 
using simple clinical (age, BMI, HbA1c), physiological measures (HOMA%B, HOMA%S) and 
the presence or absence of GAD antibodies to cluster patients with newly diagnosed 
diabetes into 5 groups { ADDIN EN.CITE <EndNote><Cite><Author>Emma 
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Spegel, Hindrik Mulder, Eero Lindholm, Olle Melander, Ola Hansson, Ulf Malmqvist, Ake 
Lernmark, Kaj Lahti, Tom Forsen, Tiinamaija Tuomi, Anders H. Rosengren, Leif 
Groop</author></authors></contributors><titles><title>Clustering of adult-onset diabetes 
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title></periodical><dates><year>2017</year></dates><urls></urls><electronic-resource-
num>https://doi.org/10.1101/186387</electronic-resource-
num></record></Cite></EndNote>}.  The initial clustering was undertaken in the ANDIS 
cohort from Sweden, with subsequent replication in three independent cohorts.  Of the 5 
subtypes – one termed ‘Severe Autoimmune Diabetes’ represents type 1 diabetes; the 
other four are termed ‘Severe Insulin Resistant Diabetes’, ‘Mild Obese Diabetes’, ‘Severe 
Insulin Deficient Diabetes’ and ‘Mild Age-Related Diabetes’.  These have marked differences 
in their rate of glycaemic deterioration, yet to date how these subgroups respond to 
different treatments has not been established, but this clustering approach offers potential 
to identify subgroups who should be best treated with one drug rather than an alternative. 
 
 
Pharmacogenetics of drug response 
 
Pharmacokinetic variation and efficacy 
For a drug to be effective it needs to reach its site of action, in its active form, before being 
cleared.  Variants that alter rate of drug transport or drug metabolism (resulting in 
activation or inactivation) will potentially alter drug exposure, resulting in increased or 
decreased efficacy.  This has been shown for both sulphonylureas, where loss of function 
variants in CYP2C9 increase glycaemic response { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
but also increase risk of hypoglycaeamia in some studies{ ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}) but not all { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}; and 
thiazolidinediones where patients with enhanced metabolism (CYP2C8*3 carriers) had 
reduced glycaemic response to rosiglitazone, whereas those with reduced transport at 
OATP1B1 had a greater response{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
 
Metformin is not metabolised, but requires to be actively transported into the liver (via the 
organic cation transporter OCT1) and into the urine (via OCT2, Multidrug and Toxin 
Extrusion MATE)1 and MATE2).  Metformin has been traditionally thought to work in the 
liver to lower hepatic glucose production.  Thus, reduced transport via OCT1 should reduce 
metformin efficacy.   Reduced function variants in SLC22A1, that encodes OCT1, have been 
shown to reduce metformin uptake into the liver (using 11C PET-Metformin tracer) { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }} yet in patients with diabetes metformin works to lower 
HBA1c just as well in the the 8% of the Caucasian population who carry two loss of function 
variants in OCT1 as those who have normal functioning OCT1 { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}.  This suggests that either with chronic dosing of metformin, OCT1 is not 
required for metformin uptake into the liver, or that the liver plays less of a role in 
metformin action than previously thought.   
 
 
Pharmacokinetic variation and adverse drug reactions 
Metformin causes gastrointestinal side effects in up to 20% of patients treated with this 
drug.  Metformin is transported from the gut lumen by the organic cation transporters OCT1 
and PMAT, and metformin is also a substrate for the serotonin transporter (SERT).  Reduced 
function OCT1 transport has been reported to be associated with increased GI intolerance in 
patients treated with metformin, an effect that is increased in patients taking concomitant 
medication that inhibits or is transported via OCT1 { ADDIN EN.CITE { ADDIN EN.CITE.DATA 
}}.  Thus, patients carrying 2 loss of function OCT1 alleles have an odds ratio for intolerance 
of 2.41 (95% CI 1.22-2.17) and this increased to an odds ratio of 4.13 (95% CI 2.09-8.16) in 
those also treated with an OCT1 interacting drug, such as proton pump inhibitors, tricyclic 
antidepressants and verapamil).  The Serotonin transporter also plays a role, with an 
interaction reported between SERT and OCT1 for metformin intolerance { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}. 
 
 
Genome wide association studies reveal novel biological mechanisms for metformin 
Genome wide association studies are now commonly applied across all disease areas and 
have provided remarkable insight into the biological mechanism of many diseases.  
However, there have been limited application of GWAS in pharmacogenetic studies, and in 
diabetes the only reported GWAS are for glycaemic response to metformin.  These studies 
have established that the chip-based heritability for this trait is high ~34% { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}; all chromosomes contribute equally to this heritability suggesting 
that there are likely to be multiple common variants with small effect similar to the genetic 
architecture of diabetes.   Thus, large sample sizes will be needed to identify variants 
associated glycaemic response to diabetes treatments.  The initial metformin GWAS 
included a discovery cohort of ~1024 and a total sample size of 3920 patients with diabetes 
treated with metformin, and identified a variant associated with treatment success at a 
locus including the ATM gene{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}; this result has 
subsequently been replicated in some studies { ADDIN EN.CITE 
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and variant remain under investigation, however ATM is the prime candidate as patients 
with Ataxia Telangiectasia, who have recessive mutations in ATM, have been shown to have 
dysglycaemia and insulin resistance { ADDIN EN.CITE 
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replication cohorts as part of the MetGen consortium ({ HYPERLINK 
"http://www.pgrn.org/metgen.html)" } to a total sample size of 13,123 and identified an 
additional genome wide significant variant for glycaemic response to metformin { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}.  This variant, rs8192675, was shown to be the top cis-
eQTL (a genetic variant altering mRNA expression) for SLC2A2 in human liver samples, and 
in the Genotype Tissue Expression project database (GTEX) was shown to be associated with 
altered expression of SLC2A2 in the pancreatic islets, the intestine and the kidney { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}.  Obese patients who were C-allele homozygotes at 
rs8192675 had a 0.33% (3.6mmol/mol) greater absolute HbA1c reduction than T-allele 
homozygotes – equivalent to 500mg difference in metformin dose and at a level that could 
be used to guide therapeutic decision making.  However, the main implication of these 
studies is in highlighting their potential to reveal novel biological mechanism of action for 
metformin.   Large meta-gwas of glycaemic response are now underway in the MetGen 
consortium, expanding the GWAS from ~1000 to more than ~20,000 metformin treated 
patients.  This has the potential to yield further novel biology and drug targets, but also, by 
combining genetic variants, the potential to predict larger drug effects that could be 
translated into clinical care.  
 
Beyond glycaemia 
As highlighted in the introduction, pharmacogenetics in diabetes should not simply focus on 
glycaemic response to drugs but should consider hard outcomes such as cardiovascular 
disease risk and mortality.  To undertake gene*treatment interactions evaluating such 
outcomes will require linkage of large genomic bioresources to electronic health record 
data; this is an area of rapid expansion and is a focus of consortia such as the EMERGE 
network ({ HYPERLINK "https://emerge.mc.vanderbilt.edu" }).  However, genetic studies can 
already be used to provide insight into the potential benefit or harm of diabetes drugs, in 
the absence of a large drug-outcome database.  For example, a recent study { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }} identified that a GLP-1 receptor variant, that is associated 
with lower glucose, was associated with reduced risk of cardiovascular disease in large case 
control studies suggesting that GLP-1RA should have beneficial cardiovascular outcomes – 
an effect now being reported in cardiovascular outcome trials for these drugs { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}.  In another example, Emdin et al. used genetic variation in 
the ABCC8 gene to address the controversial question of whether Sulphonylureas cause 
increase cardiovascular mortality, as has been suggested by observational studies e.g. { 
ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  They used the A1369S variant as a genetic proxy 
for sulphonylurea action, as functional studies show that the variant reduces KATP channel 
function, and establish that people who carry this variant have reduced risk of coronary 
heart disease suggesting that sulphonylureas should not have adverse cardiovascular 
outcomes { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.   
 
Conclusions and future directions 
There is increasing evidence that genetic variation alters response to diabetes treatments – 
both in terms of glycaemic response and side effects.  Other than in monogenic diabetes 
these have yet to impact on clinical practice, yet the effect sizes (e.g. for metformin 
intolerance and OCT1 variants; or for metformin action and SLC2A2 variants) are potentially 
of clinical utility, especially if the genotype is already known at the point of prescribing.  
With falling sequencing costs, it is likely that within the next decade individual whole 
genome or exome data will be embedded within the clinical record making the potential 
utility of the variants described a reality.  Soon, we will also be undertaking much larger 
pharmacogenetic GWAS with the potential to identify many more variants that will yield 
more insights into the mechanism of action of diabetes treatments with the potential for 
novel target identification, and by linkage to large electronic health care record systems, we 
will be able to link genetic variation to the long-term outcomes of these drugs.   
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Figure legend 
 
Figure 1.  Pharmacogenetic approaches in diabetes.  Two parallel approaches can be used to 
identify patient subgroups who respond well or poorly to diabetes treatments or to discover 
novel biological mechanisms of drug action.  One approach is to use large scale diabetes 
case-control cohorts to identify genetic variants associated with disease risk and to then 
investigate these individually or grouped by shared pathophysiology for drug response.  The 
alternative, classic pharmacogenetic approach, is to undertake a gene * drug interaction 
study to identify variants that are associated directly with altered drug outcomes.   
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